Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment

C. Leigh Moyer, Ryan Phillips, Matthew P. Deek, Noura Radwan, Ashley E. Ross, Emmanuel S. Antonarakis, Diane Reyes, Jean Wright, Stephanie A. Terezakis, Daniel Y. Song, Curtiland DeVille, Patrick C. Walsh, Theodore L. DeWeese, Michael Carducci, Edward M. Schaeffer, Kenneth J. Pienta, Mario Eisenberger, Phuoc T. Tran

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Purpose: Local ablative treatment to oligometastatic patients can result in long-term disease-free survival in some cancer patients. The importance of this treatment paradigm in prostate cancer is a rapidly evolving field. Herein, we report on the safety and preliminary clinical outcomes of a modern cohort of oligometastatic prostate cancer (OPC) patients treated with consolidative stereotactic ablative radiation (SABR). Methods: Records of men with OPC who underwent consolidative SABR at our institution were reviewed. SABR was delivered in 1–5 fractions of 5–18 Gray. Kaplan–Meier estimates of local progression-free survival (LPFS), biochemical progression-free survival (bPFS; PSA nadir + 2), distant progression-free survival (DPFS), and time-to-next intervention (TTNI) were calculated. Results: In total, 66 OPC patients were identified with consolidative SABR delivered to 134 metastases: 89 bone, 40 nodal, and 5 viscera. The majority of men (49/66) had hormone-sensitive prostate cancer (HSPC). Crude grade 1 and 2 acute toxicities were 36% and 11%, respectively, with no ≥ grade 3 toxicity. At 1 year, LPFS was 92% and bPFS and DPFS were 69%. Of the 18 men with HSPC who had deferred hormone therapy , 11 (56%) remain disease free following SABR (1-year ADT-FS was 78%). In 17 castration-resistant men, 11 had > 50% prostate-specific antigen (PSA) declines with 1-year TTNI of 30%. Conclusions: Consolidative SABR in OPC is feasible and well tolerated. The heterogeneity and small size of our series limit extrapolation of clinically meaningful outcomes following consolidative SABR in OPC, but our preliminary data suggest that this approach warrants continued prospective study.

Original languageEnglish (US)
Pages (from-to)2623-2629
Number of pages7
JournalWorld journal of urology
Issue number12
StatePublished - Dec 1 2019


  • Androgen-deprivation therapy
  • Oligometastatic prostate cancer
  • Stereotactic ablative radiation therapy

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment'. Together they form a unique fingerprint.

Cite this